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SUMMARY 
Osteoarthritis is a common and important problem in performance horses and 
symptoms include lameness accompanied with heat, pain and joint swelling. 
Several different diagnostic methods exist. However, detection of early stages of 
inflammation is problematic; hence assays for biochemical markers, such as the 
cytokines, are considered a possible way to monitor inflammation. Many of the 
cytokines are mediators released in the process of inflammation and one important 
example is tumor necrosis factor alpha (TNFα).  
In this pilot study of five horses, an ELISA was used to measure TNFα in synovial 
fluid from fetlock joints. This was performed in order to evaluate if any 
inflammatory reaction against intra-articularly injected hyaluronan X (hyaluronic 
acid) was present. Hyaluronan X is a new product with a higher molecular weight 
compared to hyaluronic suspensions commonly used in equine practice for the 
treatment of osteoarthritis.  
All the horses showed clinical signs of joint inflammation at some point. 
However, only one of the five horses presented a detectable level of TNFα in 
synovial fluid from the fetlock joint. Unfortunately, the hyaluronan X had been 
contaminated with ethanol during the manufacture and hence no conclusions 
about the side effects of this new hyaluronic suspension could be drawn. In future 
studies, a revised study design with repeated sampling of synovial fluid from 
experimental joints as well as control joints must be developed. In addition, the 
manufacturing of the hyaluronic suspension must be improved.    
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SAMMANFATTNING 
Ledinflammation (osteoartrit) är ett viktigt problem hos arbetande hästar och 
manifesteras som hälta med associerad värme, smärta och ledsvullnad. Flera olika 
diagnostiska metoder finns att tillgå men tidiga stadier av inflammation är svåra 
att upptäcka. Därför analyseras olika biokemiska och inflammatoriska markörer i 
både ledvätska och serum. Dessa markörer inkluderar de olika mediatorer som 
frisätts i samband med den inflammatoriska processen i leden och ett viktigt 
exempel är inflammationscytokinen tumör-nekros-faktor alfa (TNFα).  
I den nedan beskrivna pilotstudien med fem hästar injicerades kotleden i ett 
framben med hyaluronsyra X och den kontralaterala leden användes som kontroll. 
Hyaluronsyra X är en ny produkt med högre molekylvikt än de som idag används 
vid behandling av osteoartrit hos häst. En hästspecifik ELISA användes sedan för 
mätning av TNFα i ledvätska. Tanken med detta var att utvärdera huruvida 
injektionen av hyaluronsyra X gav upphov till en inflammatorisk reaktion i leden.  
Alla fem hästarna i studien visade kliniska tecken på ledinflammation men bara en 
av dem hade ett förhöjt värde av TNFα i kotleden. Tyvärr var 
hyaluronsyrasuspensionen vid ett par tillfällen kontaminerad av etanol vilket i sig 
kan leda till inflammation i leden. Därför kan inga slutsatser om eventuella 
biverkningar av preparatet dras från denna studie. Inför uppföljande studier bör 
tillverkningen av hyaluronsyra X förbättras och kvalitetssäkras. Dessutom måste 
studiedesignen förändras så att upprepade ledvätskeprover tas från både 
försöksleden och kontrolleden vid samma tillfällen.   
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ABBREVIATIONS 
COX  Cyclooxygenase 
ELISA  Enzyme-linked immunosorbent assay 
IGF  Insulin-like growth factor 
IL  Interleukin 
MMP  Matrix metalloproteinases 
NO  Nitric oxide 
NADPH Nicotinamide adenine dinucleotide phosphate (reduced form) 
NSAID Non-steroidal anti-inflammatory drugs 
PGE  Prostaglandin E 
PMN  Polymorphonuclear leukocytes 
PSGAG Polysulfated glycosaminoglycans 
TGF  Transforming growth factor 
TIMP  Tissue inhibitors of the matrix metalloproteinases 
TNFα  Tumour necrosis factor alpha 
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INTRODUCTION 
Joint disease and associated lameness are common and important problems in 
performance horses. It represents a welfare issue as well as a source of economic 
loss due to veterinary expenses, limited performance and early retirements. 
Therefore, there is a demand for an efficient treatment regime. In search for new 
diagnostic and treatment possibilities, knowledge about the normal joint and the 
mechanisms behind osteoarthritis is of huge importance. For successful treatment, 
there is also a need for a correct diagnosis. In the light of this, there has been a 
search for improved diagnostic methods. Biochemical markers are an important 
part of the diagnostic future.   
Over the years, various treatments have been used with variable results. However, 
the perfect treatment is still to be found. The most important medical treatments of 
today are the non-steroidal anti-inflammatory drugs (NSAID), the glucocorticoids, 
hyaluronic acid, and the polysulfated glycosaminoglycans (PSGAG). Each one of 
these has its own specific advantages and disadvantages, and researchers are 
continuously trying to find a way to improve them. For instance, the short half-life 
of hyaluronan is an obvious drawback and this was the starting-point for the 
development of a new hyaluronan suspension.  
This suspension, here called “hyaluronan X”, is intended to persist in the joint for 
a longer time, exert an effect for a longer period of time and thus lead to a better 
result of treatment. The reason for designing this pilot study was to give the 
manufacturer an opportunity to investigate in vivo how long the suspension 
actually was present in the joints and, at the same time, control whether there was 
any side effects associated with the intra-articular injection of the suspension. The 
aim of my project was to evaluate a possible inflammatory reaction in terms of 
increased levels of one of the important biochemical mediators, namely tumor 
necrosis factor alpha (TNFα). This was done through an enzyme-linked 
immunosorbent assay (ELISA) of synovial fluid.     
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BACKGROUND 
Structure and function of normal diarthrodial joints 
A diarthrodial joint consists of two opposing cartilage-covered bones stabilized by 
peri-articular soft tissues such as muscles, tendons, ligaments and joint capsule 
(fig 1) (Caron, 2003; Palmer & Bertone, 1994). 
 
 
Fig 1: Normal joint structure (McIlwraith, 2006). 
Synovium and synovial fluid 
The synovium is the vascular connective tissue which covers all the articular 
surfaces excluding the articular cartilage. It is built up of two layers, the subintima 
and the intima. The subintimal layer, which is adjacent to the fibrous joint 
capsule, consists of fibrous, areolar and fatty tissues. It is richly supplied by blood 
vessels and this is essential for the generation of synovial fluid, the exchange of 
nutrients and metabolic wastes, as well as the nutrition of the avascular articular 
cartilage. The innermost layer, the intimal layer, consists of one to four layers of 
different synoviocytes (fig 2). First, there are the macrophage-like synoviocytes 
(type A). Their main task is phagocytosis and they clear the joint of unwanted 
particles. There are also the fibroblast-like synoviocytes (type B) which are 
responsible for the production and secretion of macromolecules and proteins 
involved in the joint metabolism. Examples include hyaluronan, collagen, 
cytokines, prostaglandin, and proteinases. These are all important in maintaining 
health but may, if unregulated, be involved in development of disease (Frisbie, 
2006b; Caron, 2003).  
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Fig 2: Synoviocytes and hyaluronan molecules (Frisbie, 2006b; page 1038). 
The synovial fluid is created through ultrafiltration of plasma. The synovial 
membrane acts as a selective barrier due to lack of basement membrane as well as 
lack of junctional complexes between the intimal synoviocytes. Large molecules 
are excluded while small components of the plasma, less than 10 kDa in size, are 
allowed through. Examples are glucose, oxygen, carbon dioxide and small 
proteins. The process is mainly controlled by a complex regulatory system of the 
synovial blood flow. It is also influenced by other factors such as the molecular 
composition of the synovial fluid. For instance, size, weight and concentration of 
hyaluronan are relevant. Other factors involved in the generation of synovial fluid 
are the degree of inflammation as well as the lymphatic drainage (Frisbie, 2006b; 
Caron, 2003; Howard & McIlwraith, 1996; Palmer & Bertone, 1994).  
Articular cartilage 
The articular cartilage is an important structure for the function of the joint. In 
conjunction with the synovial fluid, it contributes to weight-bearing and almost 
friction-less motion (Caron, 2003). It covers the subchondral plate of the articular 
bones and is normally 1-4 mm thick. However, the thickness varies by joints, 
different locations within them as well as age of the horse (Frisbie, 2006b). The 
hyaline type of articular cartilage is what predominates in mammals. It is 
characterized in adults by the lack of innervation, vascularization and lymphatic 
drainage. It is therefore dependent on nourishment through diffusion from the 
synovial fluid (Frisbie, 2006b; Ray et al, 1996).  
The cartilage is built up of a small percentage of chondrocytes surrounded by 
extracellular matrix. The latter consists mainly of water (65-80%; freely 
exchangeable with that of the synovial fluid), collagens (10-30%), and 
proteoglycans (5-10%) (Caron, 2003). Microscopically, the cartilage can be 
divided into four layers (fig. 3). The superficial (tangential) zone consists of 
elongated chondrocytes within collagen fibrils aligned parallel to the articular 
surface. In the mid (intermediate) zone, the chondrocytes are larger and more 
round. They are embedded, single or paired, in collagen fibrils in a random 
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pattern. The deep (radial) zone contains even larger chondrocytes, vertically 
arranged and contained in radially arranged collagen fibrils. The most basal layer 
is the zone of calcified cartilage consisting of chondrocytes dispersed in a 
mineralised matrix and separated from the non-calcified cartilage by the so-called 
tide line (Frisbie, 2006b; Ray et al, 1996). 
 
Fig 3: The different layers of articular cartilage (McIlwraith, 2006). 
The chondrocytes are responsible for the synthesis of extracellular matrix and 
serve to balance the proteolytic enzymes involved in the degradation of matrix 
macromolecules. In a healthy joint, there is a homeostatic relationship in a 
complex interaction between chondrocytes, biochemical mediators and 
mechanical stimuli. The cartilage loss in osteoarthritis can be ascribed to a 
disequilibrium leading to matrix degradation (Caron, 2003; McIlwraith, 1996).  
Many different collagens, both fibrillar and non-fibrillar, are found in equine 
cartilage and they provide a structural framework and give tensile strength 
(Frisbie, 2006b; Caron, 2003). Briefly, the function of the collagens depends on 
the zone; in the superficial zone, the main function is protection whereas in the 
deeper layers the collagen instead anchors the cartilage to the underlying bone 
(Caron, 2003). The most abundant collagen, accounting for 90%, is type II which 
is synthesized by and secreted from the chondrocytes. It is built up of cross-linked 
fibrils consisting of triple helices of identical amino acid chains (Ray et al, 1996). 
The rate of normal turnover of collagen is significant during growth but extremely 
slow in adults. The collagen turnover is mediated by collagenase secreted by 
chondrocytes. The collagenase is proteolytically cleaved in order to become active 
and further control of the collagenase activity occurs by specific inhibitors (Caron, 
2003; Palmer & Bertone, 1994). 
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The proteoglycans consist of a protein core with glycosaminoglycans 
(glycoproteins) attached to it. The largest and most abundant of the proteoglycans 
in articular cartilage is aggrecan. It is characterized by its ability to bind to 
hyaluronic acid by a non-covalent binding stabilized by a link protein (Frisbie, 
2006b; Ray et al, 1996). The glycosaminoglycans associated with aggrecan, 
chondroitin sulphates and keratan sulphate, contain carboxyl and sulphate groups 
which make the aggrecan highly negatively charged and thus able to bind huge 
amount of water. This makes the cartilage resistant to compressive forces (Caron, 
2003). The rate of turnover is faster than that of the collagens and, in normal 
cartilage, the synthesis by the chondrocytes is balanced to the degradation by 
extracellular proteinases (McIlwraith, 1996).  
Traumatic arthritis 
Arthritis in athletic horses typically develops after single or repetitive episodes of 
trauma. Generally, joint tissues are more resistant towards shear forces than 
repetitive trauma; a central etiologic factor is therefore the mechanical stress 
associated with exercise. The joints mostly affected are the carpal, fetlock, coffin 
and tarsal joints. Lameness accompanied with heat, pain and synovial effusion are 
common clinical signs (Caron, 2003; Howard & McIlwraith, 1996). The viscosity 
of synovial fluid decreases both due to depolymerisation of the hyaluronic acid as 
well as dilution of the synovial fluid because of inflammatory effusion (Lindholm 
et al, 1996). 
Traumatic arthritis, according to Howard & McIlwraith (1996), represents a 
collection of pathologic and clinical states. It includes components such as 
synovitis, capsulitis, direct articular damage, or subchondral bone lesion which, 
each and all, may progress into osteoarthritis. In addition, there is an 
interrelationship between them. The synovial fluid of joints with either one of 
these conditions contains endogenous products that may be responsible for the 
initiation or continued progression of any of the others. Examples of such 
endogenous products are prostaglandins, free radicals, cytokines and proteoglycan 
fragments. The pain, joint effusion, and decreased range of motion are all 
consequences of the inflamed synovium and joint capsule (Howard & McIlwraith, 
1996; Lindholm et al, 1996).  
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Osteoarthritis  
The term osteoarthritis describes a disorder of joints in which degeneration and 
loss of articular cartilage is a central feature (fig 4). Other terms exist in order to 
describe the same phenomena such as degenerative joint disease (Frisbie, 2006b). 
 
 
Fig 4: Osteoarthritis (Pain Relief Cushions, 2006). 
 
Ethiopathogenesis  
Osteoarthritis is not a single disease but rather a group of biomechanical and 
biochemical mechanisms leading to synovitis and cartilage detoriation (Trumble 
et al, 2001). Different authors have tried to sort this out by categorising the factors 
involved.  
Equine osteoarthritis may be classified due to the factors initiating the disease. 
One category of cases is usually preceded by synovitis and capsulitis and is 
typically seen in joints such as the carpus, fetlock, and distal tarsal/ 
interphalangeal joints. Another type is associated with identified injuries including 
intra-articular fractures, osteochondrosis, subchondral bone injury, and septic 
arthritis. There are also cases that appear to be associated with incidental or non 
progressive articular cartilage erosion (McIlwraith, 1996).  
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Three different pathogenetic mechanisms of osteoarthritis have been described 
(Caron, 2003; McIlwraith, 1996): 
♦ A fundamentally defective cartilage with abnormal biomechanical 
properties which fails under normal loading conditions. Possible 
etiological factors to the defective cartilage are age, osteochondrosis as 
well as trauma leading to joint inflammation and subsequent degeneration 
of the articular cartilage.  
♦ A normal cartilage which is exposed to abnormal mechanical forces. 
Under normal conditions, the articular cartilage remains healthy despite 
being subjected to large forces. This is mainly due to transmission of 
forces to the peri-articular tissues, the congruity of cartilage surfaces and 
the compliance of cartilage and subchondral bone. However, in cases of 
joint incongruity (developmental defects), loss of stability (ligamentous 
tears) or supraphysiological repetitive load, the cells and the extracellular 
matrix of the cartilage may be damaged.  
♦ An alternative mechanism of cartilage destruction is present when the 
subchondral bone is impaired with sclerosis or lytic changes. Normally, 
mechanical load leads to microfractures which are continuously healing. 
However, when the microfractures occur at an increased frequency, the 
rate of optimal healing and remodeling is exceeded and the subchondral 
bone plate and trabeculae increase in density. This results in a pathological 
sclerosis with a less compliant bone, prone to failure, and subsequent 
supra-physiological stress of the articular cartilage even at a normal load. 
As a consequence, the cartilage may be mechanically damaged.  
A more simple classification is the one offered by Trumble and co-workers 
(2001). They classify osteoarthritis as either primary or secondary with primary 
being the result of cumulative stress (repetitive trauma) and secondary a result of 
preexisting tissue abnormality (osteochondral fragmentation).  
Synovial membrane and its role in disease 
The synovial membrane may be damaged by high biomechanical load such as 
repeated trauma, instability of the fibrous capsule, or abnormalities in the joint. 
However, it may also be damaged in the absence of high biomechanical load. An 
example is increased intra-articular pressure resulting in impaired circulation in 
synovial capillaries. In addition to a primary decrease in oxygen tension in the 
joint, a possible consequence to the ischemia is a so-called reperfusion injury. 
This occurs due to the formation of xanthine oxidase from xanthine reductase in 
the conversion of ATP to hypoxanthine during ischemia. When the joint relaxes 
and reperfusion occurs, the hypoxanthine reacts with oxygen under influence of 
xanthine oxidase and the result is uric acid and oxygen-derived radicals. These 
radicals are then capable of damaging both cellular and matrix macromolecules 
(Frisbie, 2006b; McIlwraith, 1996).  
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The damaged synovial membrane is an important source of inflammatory 
mediators (Frisbie, 2006b; Caron, 2003). It is also a source of pain due to 
stimulation of pain receptors in the capsular tissues and in the subchondral bone 
(McIlwraith, 1996). 
Articular cartilage degradation 
The articular cartilage degeneration depends on the fact that, in osteoarthritis, the 
chondrocytes are unable to maintain the homeostasis in the matrix and the 
consequence is net matrix degradation. Macroscopically, this can be seen as 
fibrillation, erosions and wear lines in the articular cartilage. Upon compression, 
the cartilage is softer than normal. Superficial fibrillation, chondrone formation, 
chondrocyte necrosis and full-thickness loss of cartilage are histological 
characteristics. Other common findings are subchondral bone sclerosis, 
subchondral cystic lesions, penetration of the tidemark by blood vessels, focal 
osteonecrosis, and periarticular osteophyte formation (McIlwraith, 1996).  
The loss of proteoglycans is an important initial biochemical change in 
osteoarthritis (Caron, 2003). The up-regulation of proteoglycan synthesis by the 
chondrocytes is insufficient and thus, as the inflammation proceeds, there is a 
decreased concentration of proteoglycans in all layers of the articular cartilage 
(Ray et al, 1996). The proteoglycan loss is accompanied by a degradation of 
collagen (Caron, 2003). Other important biochemical findings are changes in the 
degree of proteoglycan aggregation as well as increased water content of the 
cartilage (Moreland, 2003; McIlwraith, 1996). This results in weakening of the 
cartilage matrix, loss of viscoelastic properties and subsequent failure under 
normal loads (Caron, 2003).  
Upon damage, there is a limited potential of articular cartilage to react in order to 
produce tissue with the same morphological, biochemical and biomechanical 
properties. Three mechanisms by which cartilage may repair are (i) intrinsic 
repair with the limited mitotic capability of the chondrocyte and its minor 
increase in collagen and proteoglycan production, (ii) extrinsic repair in which 
cartilage is formed through metaplastic change of mesenchymal components of 
the subchondral bone, and (iii) by matrix flow in which cartilage is formed at the 
edge of the articular cartilage defect and then migrate toward the centre. Several 
factors contribute to the repair process such as depth of the injury, size of the 
defect, location and relation to weight-bearing/non-weight-bearing areas as well 
as age of the animal (McIlwraith, 1996). 
In addition to the articular cartilage breakdown, there may be proliferation of new 
cartilage and bone at the joint periphery (so called osteophytes; fig 4 “bone 
spurs”). Enthesophytes are bone proliferations at the insertions of ligaments, 
tendons, or joint capsule. There are several predisposing factors which cause 
osteophyte development such as age, mechanical instability, and synovitis. It is 
important to know that osteophytes can be seen in horses without articular 
cartilage damage and without clinical significance (McIlwraith, 1996). 
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Mediators of inflammation and cartilage destruction  
The mediators of joint inflammation can be divided into two groups according to 
their availability and function; the pre-formed mediators and the induced 
mediators (Palmer & Bertone, 1994). 
The pre-formed mediators infiltrate the joint following traumatic injury to the 
synovial membrane and disruption of the blood-synovial membrane. This is 
preceded by the entrance of latent forms of non-specific mediators of 
inflammation such as kinin, histamine, products of the complement pathway as 
well as components of the blood coagulation and fibrinolytic systems. These act 
as chemoattractants for leukocytes. All potential proteins released from the 
granules of these infiltrating leukocytes are included in this group of pre-formed 
mediators. The primary granulae are a source of lysozyme, cathepsins, and serine 
proteinases and from the secondary granulae spring lysozyme, proteinases, 
collagenase and gelatinase (Palmer & Bertone, 1994). 
All of these mediators are capable of contributing to changes in the synovial fluid, 
and to some extent also to cartilage destruction. The influence on cartilage 
destruction is, however, limited due to their large size and subsequent limited 
potential of diffusion into cartilage. The lysozyme released is involved in the 
degradation of hyaluronic acid while the serine proteinases affect the proteoglycan 
content in the cartilage: Elastase, for instance, may cleave the protein core at a 
number of sites. Cathepsin G instead cleaves the largest of the link proteins and 
the hyaluronic acid is therefore disaggregated from the proteoglycan. In addition, 
the changes in the synovial fluid lead to changes in lubrication, pH and nutrition 
(Palmer & Bertone, 1994). 
Leukocyte-derived substances also stimulate macrophages, synoviocytes and 
chondrocytes; the result is synthesis of the so-called induced mediators such as 
cytokines, eicosanoids and matrix enzymes. These are significantly more 
important in the destruction of cartilage matrix since they can have an effect on 
the cellular metabolism as well as the activation or inhibition of enzymes. What 
determines the outcome of the inflammatory process in the end, however, is the 
balance of these induced mediators with their inhibitors as well as the cellular 
response. If the inflammation is halted and reversed, continued damage to the 
joint surface is unlikely. However, if the inflammation persists, it will alter the 
nutritional supply to the cartilage and the presence of mediators will continue the 
inflammation and cartilage degradation (Palmer & Bertone, 1994).  
Cytokines are a group of soluble peptides whose production is induced via 
transcriptional activation in stimulated cells. They are produced by one cell and 
exert an effect on another through an endocrine, paracrine or autocrine manner. 
By binding to specific trans-membrane receptors, they affect gene expression of 
the target cell either positively or negatively. A third characteristic of cytokines is 
that they are able to influence the production and action of other cytokines via 
specific receptors (McIlwraith, 1996; Palmer & Bertone, 1994). In joints, they are 
important for the regulation of the metabolism of the synovial membrane, bone, 
and articular cartilage (Caron, 2003).  
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The cytokines has been discussed as being catabolic, modulatory or anabolic 
(Frisbie, 2006). The two most important catabolic (pro-inflammatory) cytokines 
are interleukin 1 (IL-1) and tumour necrosis factor alpha (TNFα). These are 
secreted from chondrocytes and synoviocytes, and have been shown to be up-
regulated in osteoarthritic joints (Caron, 2003; McIlwraith, 1996). IL-1 and TNFα 
have similar effect in the process of inflammation and destruction of joints, and 
act synergistically (Frisbie, 2006; Billinghurst et al, 1995). They contribute to 
joint destruction by promoting the production of other induced mediators such as 
eicosanoids and matrix metalloproteinases (MMPs).  In addition, they inhibit the 
synthesis of aggrecan and collagen (Frisbie, 2006; Hawkins et al., 1993) as well as 
the production of the tissue inhibitors of the matrix metalloproteinases (TIMP) 
(Caron, 2003). Further, IL-1 affects the collagen synthesis resulting in formation 
of functionally inadequate repair tissue (McIlwraith, 1996; Ray et al, 1996). The 
modulatory cytokines include interleukin 4 (IL-4), interleukin 10 (IL-10) and 
interleukin 13 (IL-13). They inhibit the synthesis of IL-1 and promote the 
synthesis of TIMP. Interleukin 6 (IL-6), another cytokine belonging to this group, 
has a mixed mode of action and both potentiate the effects of IL-1 and promote 
the synthesis of TIMP. The production of IL-6 is mainly stimulated by the 
catabolic cytokines IL-1 and TNFα (Frisbie, 2006; McIlwraith, 1996; Palmer & 
Bertone; 1994). Finally, the anabolic (anti-inflammatory) cytokines include 
insulin-like growth factor (IGF) and transforming growth factor (TGF). IGF-1 is 
capable of decreasing the degradation and promoting the synthesis of matrix 
molecules. TGF-β may stimulate the production of TIMP, inhibit the production 
of MMPs (Ray et al, 1996) and inhibit IL-1-induced effects by decreasing the 
expression of the IL-1 receptor (McIlwraith, 1996; Palmer & Bertone, 1994).  
IL-1 has a unique effect compared to the other cytokines, namely the capacity to 
activate phospholipase A2 and therefore stimulate the arachidonic acid cascade 
(fig 5) (Palmer & Bertone, 1994). One important arachidonic acid metabolite in 
osteoarthritis is the eicosanoid prostaglandin E2 (PGE2) which is produced by the 
chondrocytes as a response to IL-1 and to mechanical trauma.  PGE2 causes a 
decrease in the proteoglycan content of cartilage matrix. Vasodilatation, 
enhancement of pain perception, and bone demineralisation are other actions of 
PGE2 in joints. The concentration of PGE2 is low in normal joints but has been 
shown to increase in joints with osteoarthritis and lameness (McIlwraith, 1996; 
Palmer & Bertone, 1994). 
 
Fig 5: Arachidonic acid cascade (Caron & Genovese, 2003, page 746). 
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The major mediators of articular cartilage matrix depletion are considered to be 
the MMPs (fig 6), stemming from the matrix as well as from synovial membrane, 
blood, synovial fluid, and bone. The MMPs are characterised by a requirement for 
Zn2+ and Ca2+ (Caron, 2003; McIlwraith, 1996). They are synthesized by 
synoviocytes and chondrocytes, and are found in increased concentrations in 
diseased cartilage. Due to their ability to digest all major components of the 
extracellular matrix, they play a major role in articular cartilage matrix 
degradation (Frisbie, 2006). There are many different MMPs in the articular 
tissues and they may be divided into classes according to the type of cartilage 
substrate that they degrade. For instance, the collagenases cleave intact type II 
collagen, the stromelysins digest partially degraded collagen, proteoglycans, and 
other minor cartilage proteins, and the gelatinases degrade a broad spectrum of 
substrates (Caron, 2003). In healthy cartilage, the activity of MMPs is controlled 
at a number of levels. Besides control of synthesis and secretion, the MMPs are 
secreted as latent proenzymes and require extracellular proteolytic cleavage by a 
variety of proteinases in order to become active. Further, the MMP activity is 
regulated through direct inhibition by TIMP. In the normal articular tissues, most 
MMPs are present in an inactive latent or inhibited form.  However, as some 
studies indicate that there is a lack of TIMP in osteoarthritis and an elevated 
activity of MMPs such as collagenase and stromelysin (Caron, 2003; Trumble et 
al., 2001; McIlwraith, 1996). 
 
Fig 6:  Mediators of articular cartilage matrix degradation (McIlwraith, 2006). 
In addition to these mediators, oxygen-derived free radicals are produced during 
the process of inflammation by NADPH-oxidase in the cell membranes of 
polymorphonuclear leukocytes (PMNs) and macrophages. One important example 
is hydrogen peroxide. These radicals are capable of causing damage to the 
molecules and cells in the proximity. In the joint, a direct damage to the articular 
cartilage matrix with degradation and inhibited synthesis of proteoglycan can be 
noted. In addition, an indirect damage by inactivation of TIMP and 
depolymerisation of hyaluronic acid is reported (McIlwraith, 1996; Palmer & 
Bertone, 1994). 
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Finally, worth mentioning are nitric oxide (NO) and the neuropeptides. NO is 
created in the oxidation of L-arginine upon stimulation by endotoxins and 
cytokines. Its proinflammatory actions include vasodilatation, increased vascular 
permeability as well as stimulation of the production of prostaglandins (Rang et 
al., 2003a). NO also inhibits the synthesis of proteoglycan and collagen, and 
enhances the MMP activity. In addition, NO is capable of inducing apoptosis of 
chondrocytes which contributes to reduced matrix production (Caron, 2003; 
Moreland, 2003). The neuropeptides, such as substance P, are important in pain 
sensation and also involved in the pathogenesis of the disease. For instance, when 
monocytes are exposed to substance P the result is release of the cytokines IL-1, 
IL-6, and TNFα (Rang et al., 2003a; McIlwraith, 1996). 
Markers of joint disease 
The diagnosis of equine lameness and osteoarthritis has historically relied on 
clinical symptoms and radiological examination. However, radiological changes 
are visible only in advanced stages of disease and poorly correlated with clinical 
signs, synovitis and cartilage degeneration. Therefore, researchers are trying to 
find biological markers, such as inflammatory mediators or products from 
articular cartilage destruction, in synovial fluid and serum which would be helpful 
in diagnostics. These markers would make it possible to detect early changes, 
preferably before any structural damage has occurred, as well as mild chronic 
joint disease or cartilage destruction prior to clinical lameness. This would open 
new possibilities for evaluation of different treatment regimes and hence render a 
more accurate prognosis (Van den Boom et al, 2004; Bertone et al., 2001; Ray et 
al., 1996; Billinghurst et al, 1995).  
TNFα is one possible marker of joint inflammation. A higher concentration of 
TNFα in synovial fluids from joints with acute severe joint disease compared to 
normal joints has been found (Bertone et al., 2001; Billinghurst et al, 1995). 
However, this increase is not present in degenerative joints in general 
(Billinghurst et al, 1995), and a correlation between TNFα activity in synovial 
fluids and degree of joint damage has not been found (Jouglin et al., 2000). The 
conclusion from the presented research, so far, is that an increase in the 
concentration of TNFα in synovial fluid is a good predictor of acute arthritis. In 
these cases, the presence of synovitis is partly responsible for the increase of 
TNFα. Chronic osteoarthritis or cases with a cartilage defect but no synovitis fail 
to correlate with TNFα values (Bertone et al., 2001). The peak of TNFα level has 
been found to occur early in the process of experimentally induced inflammation 
and some researchers report as early as 2-4 h after onset of inflammation 
(Cornelissen et al., 1998; Billinghurst et al, 1995; Hawkins et al., 1993).  
Other possible markers, such as IL-6 and PGE2, have been proposed for detecting 
the presence of joint disease but the research, so far, has not managed to correlate 
the cytokine levels with specific joint pathology. IL-1, as TNFα, is a good 
predictor in acute severe cases but cannot adequately detect joint disease in 
general. On the other hand, PGF1α has high sensitivity and specificity for chronic 
cases. However, since severe and/or chronic cases of osteoarthritis often may be 
diagnosed with already existing means (clinical examination, radiology, and 
ultrasound), these biochemical markers are of limited use (Bertone et al., 2001).  
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Medical treatment of joint disease 
Treatment of equine osteoarthritis serves two aims; symptomatic relief and 
arresting or slowing the progression of joint degeneration. There are different 
ways of administrating the drugs; oral intake or injections (intra-muscular, intra-
venous or intra-articular).  
NSAID 
The role of the non-steroidal anti-inflammatory drugs (NSAIDs) in the treatment 
of osteoarthritis is attributable to the fact that they are relatively inexpensive and 
generally effective in reducing lameness (Caron, 2005). Further more, they are 
easily administrated in the form of oral preparations. Intervention of the 
arachidonic acid cascade (inhibition of cyclooxygenases COX-1 and/or COX-2; 
fig 5) and subsequent inhibition of the production of prostaglandins and 
thromboxanes are the main actions of NSAIDs (Rang et al., 2003a). Traditionally, 
this inhibition and the following pain relief have been considered entirely positive 
(Frisbie, 2006a). However, the actions of the prostaglandins are not entirely clear 
and there is evidence that they ambiguously also play a role in the inhibition of 
the MMPs. Thus, treatment with NSAIDs may actually increase the activity of the 
MMPs. In addition, promotion of injury may also occur through inhibition of 
chondrocyte metabolism or indirectly through increased weight-bearing due to 
pain relief. This means that the effects of NSAIDs may, in the long run, instead be 
deleterious. Importantly, there is a considerable variation between the different 
NSAIDs concerning the exact effects and side-effects (Caron and Genovese, 
2003; Palmer & Bertone, 1994). 
Glucocorticoids 
The glucocorticoids are potent anti-inflammatory agents widely used to treat 
osteoarthritis. They are capable of depressing many different inflammatory 
processes. Generally, the effects of the glucocorticoids are mediated through 
interactions with intra-cellular receptors resulting in changes in gene transcription. 
Repression of genes, for instance, results in inhibition of transcription factors 
normally involved in the production of COX-2 (and subsequently prostaglandin), 
cytokines (such as the interleukins), MMPs (e.g. collagenase), and NO. Induction 
of genes, instead, leads to formation of annexin-1. This protein has anti-
inflammatory actions through inhibition of phospholipase A2 (affecting the 
production of prostaglandin) (Rang et al., 2003b). In summary the 
glucocorticoids, in comparison to the NSAIDs, inhibit the production of 
prostaglandins by inhibiting phospholipase A2 and selectively COX-2 (fig 5) 
(Frisbie, 2006a; Rang et al., 2003a). Other anti-inflammatory effects include 
reduced influx and decreased activity of leukocytes. In addition, due to decreased 
vasodilatation and fluid exudation, the glucocorticoids are capable of preventing 
joint swelling (Rang et al., 2003b; Creamer 1997).  
Due to the risk for systemic toxic effects after oral administration, the 
glucocorticoids are normally injected directly into the affected joints and the 
suspensions generally have short intra-articular half-lives. One factor assumed to 
enable better penetration of intra-articular tissues and thus increase the duration of 
the clinical response is a period of rest following injection (Caron, 2005). As with 
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the NSAIDs, differences in the duration and therapeutic effects of the different 
preparations exist which make them suitable for different type of joints and joint 
lesions (Frisbie, 2006; Caron & Genovese, 2003).  
The importance of glucocorticoids in treatment of osteoarthritis is controversial. It 
has been shown that, at low doses, the glucocorticoids have chondroprotective 
properties due to the diminished concentration of inflammatory mediators 
otherwise leading to cartilage degradation. However, at high concentrations, the 
glucocorticoids may instead be deleterious due to suppression of proteoglycan 
synthesis and influence on the structural organization of collagens (Caron & 
Genovese, 2003). These changes are largely reversible and some researchers 
claim that inflamed joints do not exhibit the detrimental effects observed in 
normal joints after corticosteroid administration (Frisbie, 2006a; Caron 2005; 
Todhunter, 1998) Thus, Caron & Genovese (2003) argue that the risks of 
corticosteroid treatment probably are overemphasized.  
Hyaluronan  
Hyaluronic acid is a linear non-sulfated glycosaminoglycan mainly synthesized by 
the synoviocytes and the chondrocytes (fig 7). It is anionic and consequently 
associated with various cations under physiologic conditions. Therefore, more 
correctly, it is referred to as hyaluronate or hyaluronan in cases with an 
undetermined cation (Howard & McIlwraith, 1996). 
 
Fig 7: Hyaluronic acid (Läkemedelsindustriföreningen, 2006). 
Many researchers have described the physical properties of hyaluronan. 
Depending on the specific method used, the molecular mass of synovial fluid 
hyaluronan has been estimated to be in the range of 1 to 6 * 106 Da. The 
concentrations registered are between 0.33 to 1.5 mg/ml. Variations exist between 
species, between joints of the individual animal (with the smaller joints generally 
exhibiting a higher concentration) as well as between methods used (Howard & 
McIlwraith, 1996). 
Hyaluronan is a component of synovial fluid as well as of the proteoglycan 
aggregates of articular cartilage in normal joints (Howard & McIlwraith, 1996). It 
is involved in the maintenance of synovial homeostasis and viscoelasticity (Caron 
& Genovese, 2003). Different studies have indicated that reduction in size and 
synovial fluid concentration of hyaluronan accompanies the disease. 
Fragmentation of hyaluronic acid is mediated through IL-1/TNFα stimulated 
hyaluronic acid synthetase (Moreland, 2003; Howard & McIlwraith, 1996). 
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Preparations exist for administration either intramuscularly, intravenously or 
directly into the joint; with the latter being the most studied. One mechanism of 
action of exogenously administrated hyaluronan concerns its anti-inflammatory 
effect; receptor-mediated or via physical mechanisms (Caron, 2005). This anti-
inflammatory effect can be attributed to reduced production of prostaglandins as 
well as to decreased production, reduced activation and increased inhibition of 
different other inflammatory mediators. Further more, the possibility of physical 
hindrance results in prevention of diffusion of deleterious substances into the 
cartilage matrix and subsequent decrease in interaction of enzymes, antigens and 
cytokines with their target cells. In addition, potential anti-inflammatory effects 
such as inhibition of chemotaxis, migration and phagocytosis of inflammatory 
cells have been demonstrated (Moreland, 2003; Howard & McIlwraith, 1996).  
A complementary mechanism of action has been described. This is the matrix 
protective effect due to stimulation of proteoglycan synthesis by the chondrocytes 
and a blocked release of proteoglycans into the synovial fluid (Caron & 
Genovese, 2003; Moreland, 2003; Palmer & Bertone, 1994). More importantly, 
hyaluronan may also protect the matrix from the catabolic effects of IL-1 and 
other mediators (Caron, 2005; Moreland, 2003). Finally, any improvement of 
health and function of the articular soft tissues in general should lead to a more 
physiologic joint environment and indirectly reduced cartilage degeneration 
(Howard & McIlwraith, 1996). 
Hyaluronan has an effect on the nociception due to decrease of hyperanalgesic 
nerve activity and attenuation of PGE2. In addition, hyaluronan has an effect on 
substance P. Further, treatment with hyaluronan may also improve synovial fluid 
viscosity and intra-articular soft tissue lubrication with an associated increase in 
range of motion (Caron, 2005; Caron & Genovese, 2003). Cross-linked 
exogenous hyaluronan has been developed for this purpose 
(viscosupplementation). Compared to other synthetic hyaluronan suspensions, it 
seems to have a longer retention time in the synovial cavity (Frisbie, 2006a).  
Due to short turn over rates, it is concluded that the effects on synovial and 
cartilage metabolism must be indirect (Caron & Genovese, 2003). Estimations of 
the half-life of exogenous hyaluronan injected into normal equine joints have 
varied; Popot and co-workers (2004) suggest it to be close to 5 hours while 
Lindholm and co-workers (1996) reported a half-life of between 9 – 16 hours 
depending on the joint studied. In diseased joints, the half-life is suggested to be 
shorter. Most of the administrated hyaluronan is cleared from the joint but a part 
of it remains associated with different synovial tissues and may, for instance, 
influence the metabolic activities of the synoviocytes (Howard & McIlwraith, 
1996). In addition, it has been shown that injection of hyaluronan also may 
stimulate synthesis of endogenous hyaluronan by the synoviocytes (Caron & 
Genovese, 2003; Moreland, 2003) leading to a more long-lasting effect.  
The effect of the molecular weight on efficacy of hyaluronan is still controversial. 
The correlation between molecular weight and clinical effect is not clear even 
though several in vitro experiments have indicated a molecular weight-dependent 
effect (Howard & McIlwraith, 1996). Aviad and co-workers (1994) suggest that 
the therapeutic effect of hyaluronan is mediated through cellular modulation and 
therefore it is not the physical properties such as molecular weight that are 
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important. However, other studies have indicated that a basal molecular mass is 
needed for effectiveness. This basal mass has been suggested to be 1 * 106 Da 
(Caron & Genovese, 2003). Another study showed a significant difference in the 
duration of soundness in horses treated with preparations of hyaluronan with a 
molecular mass > 2 *106 Da (Philips, 1989). Unfortunately, some other studies 
have demonstrated better results with hyaluronan of lower molecular mass and 
hence Caron (2005) postulates that preparations with molecular weight in the 
range of 0.5 to 2.0 * 106 Da may be optimal.   
In conclusion, hyaluronan appears to be most useful in the treatment of acute 
cases with mild to moderate synovitis and capsulitis. In treatment of more severe 
or chronic cases, hyaluronan therapy alone does not seem adequate (Frisbie, 
2006a; Caron & Genovese, 2003; Howard & McIlwraith, 1996). More research 
within this area is certainly needed. 
Polysulfated glycosaminoglycan (PSGAG) 
PSGAG suspensions for intra-articular or intra-muscular injection consist mainly 
of the glycosaminoglycan chondroitin sulphate which is normally found in the 
proteoglycans of articular cartilage. It has anti-inflammatory properties due to 
inhibition of MMP activity, PGE2 synthesis and cytokine release. It has also been 
suggested to have a chondroprotective effect, stimulate the synoviocytial 
production of hyaluronan as well as promote the synthesis of proteoglycans and 
collagen by the chondrocytes. The precise details are not reported and 
controversies about the effects exist (Frisbie, 2006a; Caron & Genovese, 2003). 
Improvements have been noted concerning clinical lameness, radiographic 
progression as well as joint morphology in cases with acute synovitis. Gaustad & 
Larsen (1995) found PSGAG as efficient as sodium hyaluronate in the treatment 
of traumatic arthritis. However, a risk of reduction in endogenous repair of 
cartilaginous lesions has been illuminated and therefore care should be taken 
when significant cartilage lesions exist (Frisbie, 2006a). In addition, there is an 
increased risk of infection following intra-articular administration of PSGAG 
(Caron, 2005) and hence PSGAG should not be administered into septic or 
acutely inflamed joints (Läkemedelsindustriföreningen, 2006).   
Combination therapies 
There has been little controlled research concerning the effects of combination 
therapies of osteoarthritis but it has been practiced for years in both human and 
equine patients. Information concerning the efficacy, however, is therefore 
subjective. For instance, it has been suggested that hyaluronan in the combination 
with glucocorticoids may help to prevent some of the potential deleterious effects 
of intra-articular corticosteroid administration (Howard & McIlwraith, 1996). 
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MATERIAL AND METHODS 
The study was approved by the Ethical Committee of Animal Experiments in 
Uppsala, Sweden.  
Group selection and sample collection 
Synovial fluid was collected from a total of 10 fetlock joints (front legs) from 5 
horses (Table 1). The inclusion criteria were that horses should be clinically sound 
(less than one degree of lameness was accepted: American Association Equine 
Practitioners (AAEP) classification 0-5, where five equals non-weight bearing) 
and, upon provocation with flexion tests, showed no more than two degrees of 
lameness. In addition, the horses should not have any signs of joint pathology at 
radiological examination. 
 Table 1: Horses included in the study 
Horse Race 
Age 
(years) 
Gender 
Experimental 
fetlock joint 
A Swedish trotter 7 Gelding Left 
B Swedish trotter 13 Mare Right 
C Swedish warmblood 20 Mare Left 
D Swedish trotter 10 Mare Left 
E Swedish warmblood 10 Gelding Left 
 
The first day (day 0), the horses arrived and were clinically examined including 
palpation of the extremities and ocular inspection at walking, trotting and trotting 
after a one-minute flexion test. This was in all cases performed by the same 
veterinarian. On day one (1), samples of synovial fluid from the experimental and 
the opposite (control) joints were aspirated and two ml of the hyaluronan X was 
injected intra-articularly into the experimental joint. The horses were then kept in 
stall rest until the next day. On day two (2), the horses were examined and gait 
asymmetries were recorded at walk, trot and after flexion test. A synovial sample 
from the experimental joint was collected. The five following days (3-7), the 
horse was kept in the stall at night and in a sand paddock in daytime. Daily ocular 
examinations were performed and on day eight (8), the horses were evaluated for 
gait asymmetries and a synovial sample from the experimental joint was collected. 
This was followed by another two weeks with the horse kept in a paddock with 
daily ocular examinations followed by a clinical examination and synovial sample 
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collection at day 15 and day 21. On day 22, the horse was anesthetized and 
euthanized. Synovial fluid from both fetlock joints of the front legs was collected 
post mortem.  
After clipping and disinfection of the skin, the synovial fluid was aspirated 
aseptically and transferred into sterile blood collection tubes. All synovial fluid 
samples were kept at 4-8 ºC for a maximum of 2 hours until centrifuged for 5 
minutes (Beckmans Microfuge Lite Centrifuge; 13000 rpm; 4 ºC). The 
supernatant was aliquoted (150-250 µl) and stored frozen (-70ºC) until analysed. 
All samples were collected within a period of 4 months and analysed within 9 
months after the first sample was collected.  
ELISA for equine TNFα 
TNFα was analysed using Equine TNFα Screening Set (Endogen, Rockford, 
USA) according to the manufacturer’s instructions except for pre-treatment with 
hyaluronidase. This was done to minimize the risk that the hyaluronic acid in the 
sample would interfere with the binding of TNFα in the assay and therefore 
remove a portion of the cytokine (Billinghurst et al., 1995). All samples were 
analyzed at one occasion.  
The 96-well plate was coated with 100 µl anti-equine antibody (3 µg/ml) per well 
overnight at room temperature (RT; 22-25 ºC).  The next day, the plate was 
washed and incubated for one hour with blocking buffer.   
All samples were treated with hyaluronidase by dissolving 10 mg of 
Hyaluronidase (Sigma) in 20 ml of Tris-Hac-Mix (SVA) to a concentration of 500 
µg/ml. Then 100 µl of each synovial sample was mixed with 100 µl of the 
hyaluronidase buffer solution, incubated at RT for 30 minutes and 200 µl of 
reagent diluent was added, resulting in four times final dilution of the sample.   
A standard curve (Fig. 8) covering a range of 7.8-1000 pg/ml was prepared using 
equine TNFα included in the kit. 100 µl of standard or sample were added to the 
wells in duplicates. The plate was covered with a plate sealer and incubated at RT 
for one hour. The plate was then washed three times with 300 µl of wash buffer 
per well. 
The detection antibody was diluted to a concentration of 0.4 µg/ml. 100 µl of the 
solution was added to each well and the plate was incubated for one hour at RT. 
The plate was washed with wash buffer and 100 µl of Streptavidin-HRP (SA-
HRP) was added to the wells and incubated for 30 minutes at RT.  
Finally, the plate was washed with wash buffer before 100 µl of substrate solution 
was added to each well and the plate was incubated in the dark for 20 minutes at 
RT. The reaction was then stopped by adding 100 µl of stop solution (0.18 M 
sulphuric acid) to each well. The absorbance was measured in a 
spectrophotometer at A450 – A550.  
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Fig 8 Absorbance vs concentration of standard. 
 
RESULTS 
Clinical response- The clinical response of the horses was summarized in another 
degree project (Thorell, 2007). All five horses showed increased synovial effusion 
the day after the injection of Hyaluronan X (day 2). In one horse (A), this 
disappeared and was not apparent on day 8. In horse B, the synovial effusion was 
still apparent day 8.  In three horses (C, D, E), the increased synovial effusion was 
present the entire period (day 2 – day 22). Three of the horses (B, D, and E) also 
showed signs of increased temperature in the skin of the experimental fetlock joint 
(subjectively estimated). Two of the horses (B, D) showed lameness day 2; horse 
D showed a 0.5 degree of lameness at the trot and horse B reacted with a one 
degree of lameness after flexion test. At day 8, these horses were no longer lame.  
The five horses in this study remained healthy throughout the study (measured as 
no signs of depression or increase in body temperature). 
Biochemical response- The synovial fluid from the experimental joint of horse C, 
at days 2 and 8 presented detectable levels of TNFα. At day 15, TNFα was again 
non detectable. In the control joint of horse C, as well as in all the samples (from 
both experimental and control joints) from the other horses, TNFα was non 
detectable (Table 2). 
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Table 2: The concentration of TNFα in the different equine samples* 
 
 
Concentration of TNFα 
(pg/ml) 
Horse 
Joint 
Day 1 Day 2 Day 8 Day 15 Day 22 
A      
EJ n.d. n.d. n.d. n.d. n.d. 
CJ n.d.    n.d. 
B      
EJ n.d. n.d. n.d. n.d. n.d. 
CJ n.d.    n.d. 
C      
EJ n.d. 142 210 n.d. n.d. 
CJ n.d.    n.d. 
D      
EJ n.d. n.d. n.d. n.d. n.d. 
CJ n.d.    n.d. 
E      
EJ n.d. n.d. n.d. n.d. n.d. 
CJ n.d.    n.d. 
 
* EJ= experimental joint; CJ= control joint; n.d.= non detectable 
 
DISCUSSION 
The purpose of this study was to evaluate if injection of hyaluronan X could be 
harmful and lead to an inflammatory reaction in the joint. This was done mainly 
by registering clinical signs of inflammation (covered in another degree project; 
Thorell, 2007) and partly by the aid of a biochemical marker. The marker chosen 
was the cytokine TNFα which, in several studies, has been concluded to be a good 
predictor of acute arthritis (Bertone et al, 2001; Jouglin et al, 2000; Billinghurst et 
al, 1995). The present study was a pilot project, designed to evaluate if any side 
effects occurred with the intra-articular administration of hyaluronan X. This was 
only done in a small number of horses (five) in order to minimise unnecessary 
pain and discomfort in a large number of horses (which will be needed in a 
clinical trial of hyaluronan X).   
Results of this study indicate that there is an inflammatory reaction after injection 
of this hyaluronan suspension. Mild transient reactions are common sequelae after 
joint injections and the importance is not clear. One of these horses, however, 
reacted with lameness. This was not the same horse which presented a detectable 
level of TNFα in synovial fluid from the fetlock joint. Explanations for this can 
only be speculative. Essential is that the joint microenvironment is complex and 
many factors interact.  
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There are other methods for analyzing TNFα in synovial fluids such as bioassays. 
There is a possibility that a bioassay would have resulted in a higher percentage of 
the horses showing an increased level of TNFα following the injection. However, 
the immunoassay used in this study is equine specific and has a high sensitivity; 
hence the results with low TNFα levels are reliable. In addition, several other 
inflammatory mediators exist that would be suitable as biochemical markers. A 
complete battery of different inflammatory mediators, such as IL-1, IL-6 and 
PGE, would serve better to identify early inflammation. It is, however, crucial that 
the assays to be used are equine specific and not only evaluated in other species.  
One possible explanation to the inflammatory reaction may be that the hyaluronan 
X, which was manufactured by an independent company, was not standardly 
produced. It was revealed that some of the samples of Hyaluronan X were 
accidentally contaminated by ethanol. Various alcohols, such as polyvinyl alcohol 
and ethyl alcohol, have in prior studies been shown to be irritative to the joint 
structures (Shoemaker, R.W. et al., 2006; Cornelissen et al., 1998). Therefore, 
there is a risk that the ethanol in the suspension injected, per se, might have 
caused the inflammatory reaction. Before any conclusions can be made of the 
reactions to hyaluronan X, the process of manufacturing must be properly 
standardised and optimised in order to avoid, for instance, contamination. 
However, the results may also have been influenced by the design of the study. In 
order to completely evaluate the effect of hyaluronan X, there is a need for 
repeated sampling from a control joint as well. In this study, the opposite fetlock 
joint was used as a control. However, synovial fluid was only collected from this 
control joint at two occasions; the null sample (day 1) and the sample post mortem 
(day 22). The fact that the number of samples from the experimental joints and the 
control joints was not equal is a potential drawback; the arthrocentesis per se 
could be assumed to elicit an inflammatory response and hence a corresponding 
increase in the level of TNFα in the experimental joint. In that case, an increased 
level of TNFα in samples from the experimental joint could not be concluded to 
exclusively originate from the injected substance. However, while there are 
studies showing a small and limited increase in inflammatory cells following 
synovial aspiration, a number of studies have failed to show any effect of serial 
arthrocentesis on synovial TNFα (van den Boom et al, 2004; Billinghurst et al, 
1995; Wagner et al, 1982). In addition, Lohmander et al (1998) found that weekly 
aspiration of synovial fluid was not a confounding factor in longitudinal human 
patient studies. They conclude that weekly injections neither have an effect on 
joint tissue metabolism nor induce synovitis. Also, the present study did not reveal 
high levels of TNFα indicating an inflammatory response to repeated 
arthrocentesis. Only synovial samples from one horse showed detectable TNFα 
levels. Therefore, this should not represent a confounding factor in the present 
study. However, repeated sampling of synovial fluids from experimental as well 
as control joints should be considered in future studies.     
In addition, the control joints of the five horses did not receive any injected 
solution at all. Injection of any substance into control joints constitutes a potential 
problem since there is no obvious optimal substance. The most natural substance 
available should be isotonic saline solution. However, studies with saline 
injections have shown an effect on the joint microenvironment in both normal and 
diseased joints (Gaustad et al., 1999; Gaustad & Larsen, 1995). This indicates that 
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saline solution is not an optimal choice. Further, there are also reports describing 
an inflammatory response after injection of isotonic saline solution. This 
inflammatory response was manifested as an increased leukocyte count, a 
parameter which has been correlated with TNFα concentration in other studies 
(Bertone et al., 2001; Hawkins et al., 1993; Wagner et al., 1982) 
CONCLUSION 
From this study, no conclusions can be drawn about the side effects of hyaluronan 
X. Improvements in the manufacture of the suspension, as well as the design of 
the study, are necessary. 
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